Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7PCLY)

Drug Name
ARC1779 Drug Info
Indication
Disease Entry ICD 11 Status REF
Intracranial embolism 8B22.1 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM7PCLY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
von Willebrand factor (VWF) TT3SZBT VWF_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
von Willebrand factor (VWF) DTT VWF 3.459 8.185 6.67 8.541
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Intracranial embolism
ICD Disease Classification 8B22.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
von Willebrand factor (VWF) DTT VWF 2.96E-01 2.47 2.08
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00742612) Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy. U.S. National Institutes of Health.
2 Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.